Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine

Vaccine

Volumn 17, Issue 22, 1999, Pages 2918-2926

  Hagiwara, Yukari ^a,b   Komase, Katsuhiro ^b   Chen, Ze ^a   Matsuo, Kazutoshi ^a   Suzuki, Yujiro ^b   Aizawa, Chikara ^b   Kurata, Takeshi ^a   Tamura, Shin Ichi ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b KITASATO INSTITUTE   (Japan)

Author keywords

Adjuvant; Mucosal immunity; Mutant cholera toxin; Nasal influenza vaccine

Indexed keywords

CHOLERA TOXIN; HEMAGGLUTININ; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; INFECTION RESISTANCE; INFLUENZA; INFLUENZA VACCINATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CHOLERA TOXIN; DRUG STABILITY; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN E; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; MUTATION; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, SYNTHETIC;

EID: 0033575433     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00135-8     Document Type: Article

References (44)

1. Dallas W.S., Kalkow S. Amino acid homology between cholera toxin and Escherichia coli heat-labile toxin. Nature. 288:1980;499-501.
2. Sixmaa T.K., Pronk S.E., Kalk K.W., Wartna E.S., van Zanten B.A.M., Witholt B., Hol W.G.J. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature (Lond.). 351:1991;371-377.
3. Spanglar B.D. Structure and function of cholera toxin and related Escherichia coli enterotoxin. Microbiology Reviews. 56:1992;622-647.
4. Elson C.O., Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. Journal of Immunology. 133:1984;2892-2897.
5. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 59:1986;301-308.
6. Clements J.D., Hartzog N.M., Lyon F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine. 6:1988;269-277.
7. Tamura S-I., Shoji Y., Hashigucci K., Aizawa C., Kurata T. Effect of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin. Vaccine. 12:1994;1238-1240.
8. Snider D.P., Marshall J.S., Perdue M.H., Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. Journal of Immunology. 153:1994;647-657.
9. Bergquist C., Johansson E-L., Lagergard T., Holmgren J., Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infection and Immunity. 65:1997;2676-2684.
10. McKenzie S.J., Halsey J.H. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. Journal of Immunology. 133:1984;1818-1824.
11. Wu H-Y., Russell M.W. Induction of mucosal immunity by intranasal application of a Streptococcal surface protein antigen with the cholera toxin B subunit. Infection and Immunity. 61:1993;314-322.
12. Schodel F., Will H. Construction of a plasmid for expression of foreign epitopes as fusion proteins with subunit B of Escherichia coli heat-labile enterotoxin. Infection and Immunity. 57:1989;1347-1350.
13. Dertzbaugh M.T., Peterson D.L., Macrina F.L. Cholera toxin B-subunit gene fusion: structural and functional analysis of the chimeric protein. Infection and Immunity. 58:1990;70-79.
14. Wilson A.D., Clarke C.J., Stokes C.R. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scandinavian Journal of Immunology. 31:1990;443-451.
15. Tamura S-I., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., Suzuki Y., Nagamine T., Kawahara K., Danbara H., Aizawa C., Oya A., Kurata T. Synergistic action of cholera toxin B subunit (and E. coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine. 12:1994;419-426.
16. Tamura S-I., Asanuma H., Tomita T., Komase K. Kawahara K., Danbara H., Hattori N., Watanabe K., Suzuki Y., Nagamine T., Aizawa C., Oya A., Kurata T. Escherichia coli heat labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine. 12:1994;1083-1089.
17. Liang X., Lamm M.E., Nedrud J.G. Cholera toxin as a mucosal adjuvant. Glutaraldehyde treatment dissociates adjuvanticity from toxicity. Journal of Immunology. 143:1989;484-490.
18. Douce G., Turcotte C., Cropley I., Roberts M., Pizza M., Domenghini M., Rappuoli R., Dougan G. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvant. Proceedings of National Academy of Sciences USA. 92:1995;1644-1648.
19. Douce G., Fontana M., Pizza M., Rappuoli R., Douga G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infection and Immunity. 65:1997;2821-2828.
20. Yamamoto S., Takeda Y., Yamamoto M., Kurazono H., Imaoka K., Yamamoto M., Fujihashi K., Noda M., Kiyono H., McGhee J.R. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. Journal of Experimental Medicine. 185:1997;1203-1210.
21. Yamamoto S., Kiyono H., Yamamoto M., Imaoka K., Yamamoto M., Fujihasi K., VanGinkel F.W., Noda M., Takeda Y., McGhee J.R. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proceedings of National Academy of Sciences USA. 94:1977;5267-5272.
22. Komase K., Tamura S-I., Matsuo K., Watanabe K., Hattori N., Odaka A., Suzuki Y., Kurata T., Aizawa C. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine. Vaccine. 16:1998;248-254.
23. Hashigucci K., Ogawa H., Ishidate T., Yamashita R., Kamiya H., Watanabe K., Hattori N., Sato T., Suzuki Y., Nagamine T., Aizawa C., Tamura S-I., Kurata T., Oya A. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine. 14:1996;113-119.
24. Hashigucci K., Tamura S-I., Kurata T., Kamiya H., Ishidate T. Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers. Journal of the Japanese Association for Infectious Diseases. 71:1997;153-161.
25. Tamura S-I., Asanuma H., Ito Y., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T., Oya A. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza HA vaccine. European Journal of Immunology. 22:1992;477-481.
26. Tamura S-I., Funato H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different haemagglutinin molecules. European Journal of Immunology. 21:1991;1337-1344.
27. Tamura S-I., Ito Y., Asanuma H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. Journal of Immunology. 149:1992;981-988.
28. Tamura S-I, Kurata T Intranasal immunization with influenza vaccine. In: Kiyono H, Ogra PL, McGhee JR, editors. Mucosal vaccines, ch. (Chap. 32). San Diego: Academic Press, 1996. p. 425-436.
29. Burnette W.N., Mar V.L., Platler B.W., Schlotterbeck J.D., McGinley M.D., Stoney K.S., Rohde M.F., Kaslow H.R. Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity. Infection and Immunity. 59:1991;4266-4270.
30. Davenport F.M., Hennessy A.V., Brandon F.M., Webster R.G., Barrett C.D. Jr, Lease G.O. Comparison of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinin. Journal of Laboratory and Clinical Medicine. 63:1964;5-13.
31. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 77:1989;51-59.
32. Uesaka Y., Osuka T., Lin Z., Yamasaki S., Yamaoka J., Kurazono H., Takeda Y. Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose. Microbial Pathogenesis. 16:1994;71-76.
33. Nakamura S., Morita T., Iwanaga S., Niwa M., Takashi K. A sensitive substrate for the clotting enzyme in horseshoe crab hemocytes. Journal of Biochemistry. 81:1977;1567-1569.
34. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
35. Donta S.T., Moon H.W., Whipp S.C. Detection of heat-labile Escherichia coli enterotoxin with the use of adrenal cells in tissue culture. Science. 183:1974;334-336.
36. Tamura S-I., Miyata K., Matsuo K., Asanuma H., Takahashi H., Nakajima K., Suzuki Y., Aizawa C., Kurata T. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. Journal of Immunology. 156:1996;3892-3900.
37. Marinaro M., Staats H.F., Hiroi T., Jackson R., Coste M., Boyaka P.N., Okahashi N., Yamamoto M., Kiyono H., Bluethman H., Fujihashi K., McGhee J.R. Mucosal adjuvant effect of cholera toxin in mice results from induction of helper 2(Th2) cells and IL-4. Journal of Immunology. 155:1995;4621-4629.
38. Sakaguchi M., Inoue S., Miyazawa H., Tamura S-I. Measurement of antigen-specific mouse IgE by a fluorometric reverse (IgE-capture) ELISA. Journal of Immunological Methods. 116:1989;181-187.
39. Tamura S-I., Ishizaka K. Reaginic antibody formation in the mouse. X. Possible role of suppressor T cells in transient IgE antibody responses. Journal of Immunology. 120:1978;837-843.
40. Tsuji T., Inoue T., Miyama A., Okamota K., Honda T., Miwatani T. A single amino acid substitution in the A subunit of Escherichia coli enterotoxin results in a loss of its toxic activity. Journal of Biological Chemistry. 265:1990;22520-22525.
41. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxin is linked to their ADP-ribosyltransferase activity. European Journal of Immunology. 22:1992;2277-2281.
42. Harford S., Dykes C.W., Hobden A.N., Read M.J., Halliday I.J. Inactivation of the Escherichia coli heat-labile enterotoxin by in vitro mutagenesis of the A-subunit gene. European Journal of Biochemistry. 183:1989;311-316.
43. Elson C.O., Ealding W. Genetic control of the murine immune response to cholera toxin. European Journal of Immunology. 135:1985;930-932.
44. Hirabayashi Y., Tamura S-I., Suzuki Y., Nagamine T., Aizawa C., Shimada K., Kurata T. H-2-unrestricted adjuvant effect of cholera toxin B subunit on murine antibody responses to influenza virus haemagglutinin. Immunology. 72:1991;329-335.